In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal. December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 26 Nov 2025 Beyond GLP-1s: is there a new wave of metabolic disease treatments? A new wave of metabolic disease treatments beyond GLP-1 agonists is emerging to address the unmet needs of patients. November 26, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2025 Top biotech deals in July 2025 Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery. August 8, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2025 Metabolomics: The study of biology’s dark matter Learn about metabolomics, biology’s fourth language that has remained vastly untapped up until now and could accelerate biotech research. April 14, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2025 Top biotech deals of March 2025 Learn about the top biotech deals of March 2025. Small molecules, bispecific antibodies, and protein therapies were all part of major collaborations. April 2, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 November has seen a variety of biotech deals take place to advance therapies across different stages in development. December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 20 Nov 2024 Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024 The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials. November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Oct 2024 GPCR therapies: Eight promising biotechs hacking the cell signaling pathway In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines. October 29, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2024 Long non-coding RNAs: what’s behind the growing “dark genome” buzz? Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front. September 10, 2024 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Sep 2024 Six biotech companies that could revolutionize obesity treatments In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market. September 5, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year. June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2024 MASH candidates make a splash after first drug approval The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients. June 19, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email